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Abstract
Background: Growth factor-containing products have been reported to increase implant stability and accelerate
osseointegration. Concentrated growth factor (CGF) can be used for this purpose with the growth factors it
contains. The aim of this study is to assess the effect of CGF on implant stability and osseointegration.
Methods: Twelve patients with maxillary anterior toothless were included in the study. Implant cavities prepared in
the study group were covered with CGF membrane before implant placement, but conventional implant
placement was performed in the control group. Resonance frequency measurements were performed with the
Osstell device intra-operatively, post-operatively, at the 1st week, and at the 4th week.
Results: The mean ISQ values were found to be 79.40 ± 2.604 for the study group and 73.50 ± 5.226 for the control
group at 1st week, 78.60 ± 3.136 for the study group and 73.45 ± 5.680 for the control group at 4th week.
The differences between the groups were statistically significant (p < 0.05).
Conclusions: It was observed that the concentrated growth factor had positive effects on implant stabilization.
The ISQ measurements at week 1 and week 4 were notably higher in the study group. Application of this material
seems to accelerate osseointegration.
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Background
Osseointegration of dental implants is important for long-
term success and stability. There is no standardization in
terms of the time of osseointegration and the timing of
prosthetic loading. This process varies between 0–
6 months [1]. Various strategies are being explored to
shorten this period. Changes in implant surface properties
and design have increased primer stability and helped the
peri-implant tissue remain healthy. These changes have
aimed to increase bone-implant surface connectivity and
accelerate healing. Another method of accelerating
osseointegration is the modulation of healing after the
placement of the implant [2]. This modulation, in turn,
can be achieved by bioactive molecules that increase
osteoblastic differentiation and accelerate bone healing
around the implant [2].
Growth factors are bioactive proteins that control the
wound healing process. The platelet-containing preparations
derived from human blood contain many growth factors
such as bone morphogenetic protein (BMP), platelet-derived
growth factor (PDGF), insulin-like growth factor (IGF),
vascular endothelial growth factor (VEGF), transforming
growth factor-β1 (TGF-β1), and transforming growth
factor-β2 (TGF-β2), which also play a key role in bone
healing [3–5]. These growth factors attract the undifferenti-
ated mesenchymal cells to the wound site, thus facilitating
angiogenesis, chemotaxis, and cell proliferation [2].
Various platelet concentrates such as platelet-rich
plasma (PRP), platelet-rich fibrin (PRF), and concentrated
growth factor (CGF) are used to reconstruct bone defects
[6]. PRF has been shown to have very successful results in
tissue engineering in many studies [7–9]. Furthermore, a
study by Sohn et al. has shown the higher regeneration
capacity and multipurpose use of CGF in 2009 [10].
This preparation’s potential is because it contains
growth factor-containing fibrin network; it contains fibro-
blast, platelet, leukocyte, and endothelial cell for angiogen-
esis and tissue remodeling; and it provides matrix for cell
migration [11]. Platelets, in particular, contain biologically
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active proteins at high concentrations and support heal-
ing, growth, and cell morphogenesis [12–14].
That the implant has sufficient stability after placement
is important for providing the necessary bone formation
around the implant and for the optimal distribution of
functional forces at the implant-bone interface during
healing [15–17].
It can be said that resonance frequency analysis (RFA)
is a very important tool for tracking the osseointegration
process [18, 19]. RFA is a technique that allows tracking
the changes in stability not only during implant place-
ment but also during healing and later periods [20].
Growth factor-containing products have been shown
to accelerate bone healing and osseointegration [2, 4]. In
this study, it is aimed to evaluate the effect of CGF on
implant stability. Based on the results obtained in the
study, it will be possible to reduce the amount of time
required for osseointegration.
Methods
This study was conducted in compliance with the principles
of the Declaration of Helsinki, and approval of the ethics
committee required for the study was obtained from the
Ethics Committee of the Karadeniz Technical University
(2015/21). The procedures to be performed were explained
in detail and patients signed the consent forms. The study
was carried out on individuals who applied to Karadeniz
Technical University, Faculty of Dentistry, Department of
Oral and Maxillofacial Surgery to get dental implants for
upper jaw tooth deficiencies. In terms of standardization,
only patients with implants applied to maxillary anterior
and premolar region were included in the study. Cylindrical
implants were used in each patient. The diameter of the
implant was 3.5 or 4.0 mm, and the length was 10 mm. In
patients who underwent tooth extraction, implants were
placed 6 months after extraction. Patients rehabilitated with
a fixed prosthesis, such as a single crown or bridge, were
included in the study. Patients included in the study were
randomly assigned to two groups: study and control
groups.
Exclusion criteria were identified as:
 Presence of systemic diseases preventing
implantation
 Having blood disease to prevent centrifugation
 Previous implantation or augmentation of the same
region
 The need for additional bone augmentation
procedures (such as maxillary sinus augmentation,
distraction osteogenesis)




The implanted regions were evaluated preoperatively
with panoramic radiography and computed tomography
(CT) images. In the study group, the socket walls were
laid with CGF membrane while the implant surfaces
were washed with the thrombocyte-deprived part of the
tube. No different procedure was done to the implants
and socket in the control group.
CGF preparation
A standard, disposable, 10-ml non-anticoagulant tube and
a matching centrifuge device (MEDIFUGE, Silfradentsrl, S.
Sofia, Italy) were used. Intravenous blood samples from the
patients were placed in centrifuge tubes without anticoagu-
lants and accelerated for 30 s, centrifuged at 2700 rpm for
4 min, 2400 rpm for 4 min, 2700 rpm for 4 min, and
3000 rpm for 3 min, and decelerated for 36 s to stop. All of
these acceleration and deceleration processes are adjusted
automatically due to the centrifugal device’s feature. Three
layers were observed in the tube: red blood cell layer at the
bottom, platelet-deprived plasma layer (without cell) at the
top, and fibrin gel with concentrated growth factor and
platelet aggregation in the middle. First, the uppermost
platelet-deprived fraction was removed with a sterile syr-
inge. The layer in the form of a membrane containing the
concentrated growth membrane was held with the aid of a
hemostatic clamp, separated from the red blood cell layer
by cutting with a pair of scissors and then pressed to form
a membrane (Fig. 1).
Surgical procedure
All surgical procedures were performed under local
anesthesia by the same surgeon. A full-thickness muco-
periosteal flap was removed by incision on the alveolar
Fig. 1 CGF was obtained after centrifugation
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crest. Implant cavities were prepared according to the
surgical protocol of the Bego Semados implant system
(BEGO Implant Systems GmbH & Co. KG, Bremen,
Germany). The final osteotomy diameters were the same
as the placed implants. In the study group, the implant
cavity walls were laid with CGF membranes all around
(Fig. 2). The implants in the study group were irrigated
with CGF fluid on their surface and placed in the corre-
sponding socket (Fig. 3). The implants representing the
control group were placed in the corresponding socket
without any additional procedure. The implant surgery
was completed in one session by attaching gingival
formers to the implants in both groups. Gingival formers
were not covered with soft tissue and mucoperiosteal
flaps were sutured with 3/0 silk suture material.
The patients were recommended to apply cold compresses
after the surgery. Patients were prescribed antibiotic
(amoxicillin + clavulanic acid combination 1000 mg 2 × 1),
analgesic (arveles tablet, 25 mg 2 × 1), and antiseptic mouth-
wash (0.2% chlorhexidine gluconate mouthwash, 3 × 1) for
1 week. The patients were controlled at the 1st week, 4th
week and 12th week.
Resonance frequency analysis measurements
The stability of implants by RFA was done using Osstell
instrument (Integration Diagnostics, Goteborg, Sweden)
with Smartpeg™ (Integration Diagnostics, Goteborg,
Sweden), a transducer suitable for implants. The meas-
urement result is obtained from the resonance frequency
values by an arithmetic algorithm and given as the ISQ
(implant stability quotient) value. At measurement time,
the transducer, Smartpeg™, was placed in the region
where the prosthetic part is located in the implants.
For measurements, the Osstell™ probe was approxi-
mated to the Smartpeg™ from the buccal, palatal, mesial,
and distal sides. For each implant, resonance frequency
values were obtained in four different directions. The ISQ
values were averaged to determine the mean ISQ value for
each implant. The ISQ values of the implants were
measured during the operation, at the first week and at
the fourth week after the operation.
Statistical analysis
Independent sample t test was applied between the two
groups by taking the differences between the data ob-
tained in these periods. Two-way ANOVA and Fisher’s
LSD test was used for evaluating the associations among
group and insertion torque.
A value of p < 0.05 was considered statistically signifi-
cant. All evaluations were performed with Windows SPSS
(version 17.0, IBM Corp., NY, USA) software.
Results
The study includes 12 patients (5 males, 7 females). Pa-
tients participating in the study are between 20–68 years
of age and the mean age is 44 years. A total of 40 implants
were placed, 20 of these were included in the study group
(50%), and the other 20 were included in the control
group (50%). Twenty-one implants were placed in type 2
bone, 19 implants in type 3 bone (Table 1). The distribu-
tion of gender, installed implant diameter, and bone qual-
ity between the control group and the experimental group
did not show any statistically significant difference. No
complications occurred during the postoperative period.
At the implant placement, the average torque for study
group was 31,700 ± 2,696 Ncm and for control group
was 30,55 ± 2,163 Ncm; there was no significant differ-
ence between the two groups (p = 0.098).
The mean ISQ values measured after the placement of
the implants were 75.75 ± 5.552 for the control group
and 78.00 ± 2.828 for the study group. There was no sta-
tistically significant difference between control and study
groups in terms of initial ISQ values (p > 0.05).
Fig. 2 CGF membrane was applied in study group implant sockets
Fig. 3 Implants were placed after application of CGF membrane
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The postoperative ISQ values were found to be 79.40 ±
2.604 for the study group and 73.50 ± 5.226 for the control
group at 1st week, 78.60 ± 3.136 for the study group and
73.45 ± 5.680 for the control group at 4th week (Table 2).
It was determined that the differences between the groups
were statistically significant (p < 0.05) and the ISQ
measurements at week 1 and week 4 were notably higher
in the study group (Fig. 4).
The increase and decrease rates of ISQ values between
periods were evaluated by paired t test. Immediate postop-
erative measurements and 1st week measurements were
compared. An increase of 1.40 ± 1.847 was observed in the
study group while there was a decrease of 2.25 ± 1.713 in
the control group; this difference was statistically significant
(p < 0.001). When the difference between the immediate
postoperative measures and the 4th week measurements
were evaluated, an increase of 0.60 ± 2.798 was observed in
the study group while a decrease of 2.30 ± 2.774 was ob-
served in the control group; this difference was statistically
significant (p = 0.002). When the difference between the
measurements of the control group and the study group at
1st week and 4th week was evaluated, a decrease of 0.05 ±
1.572 was observed in the control group while a decrease
of 0.80 ± 2.215 was observed in the study group; this differ-
ence was not statistically significant (p = 0.224) (Table 3).
Discussion
Implant stability is one of the important parameters that
assess the loading time and dental implant success.
Investigators have recommended that implants with ISQ
< 49 measured when placed should not be loaded during
the 3-month healing period; implants with ISQ ≥ 54 may
be loaded. It is emphasized that implants with low pri-
mer stabilization value should be waited to reach a
stabilization value adequate for prosthetic loading and
that they must be protected against mechanical trauma
and infection during this time [21].
In some studies, there is a meaningful reduction in
ISQ values measured sometime after the placement of
implants [22–24]. Huwiler et al. [24] have indicated that
this reduction occurs during 2nd–4th week period while
Monov et al. [23] have stated that it occurs as early as
4 days after the operation. In this study also, a decrease
in the 1st week ISQ values was observed in the control
group. Investigators have suggested that this decrease in
stability values and subsequent increase are due to re-
modeling occurring during bone healing [22–24]. In the
implants in the study group, an increase or stability was
observed. A statistically significant difference was found
between the study and control groups in each period of
analysis. This suggests that CGF administration affects
the implant primer stability by accelerating the osseoin-
tegration process.
Growth factors indicate that they accelerate tissue
healing when they function effectively. Studies in the lit-
erature have reported that thrombocytes secrete growth
factors from α-granules and that these releasing growth
factors promote collagen synthesis. Increased collagen
synthesis is thought to play a role in increasing soft tis-
sue resistance and in the initiation of callus formation in
bone tissue [14, 25–27].
Thrombocytes (platelets) also coexist with other throm-
bocytes, allowing the fibrin network to remain stable [28].
Within this stable, fibrin clot formation are chemical
attractants in surrounding cells such as cell adhesion
proteins, thrombocytes, and plasma growth factor; some
of these mitogens are related to direct osteogenic cell
function [29].
Introduced in 1998 by Marx, PRP is used in oral and
maxillofacial surgeries to speed up the recovery of grafts
in bone-grafted areas [14, 26–30]. Although many stud-
ies have shown that platelet-rich plasma affects bone
healing positively, the results of some other studies sug-
gest otherwise [31, 32].
In recent years, the platelet-rich fibrin (PRF) was de-
scribed by Choukroun as a second-generation platelet
concentrate [33]. PRF is defined as leukocyte and platelet-
rich fibrin biomaterial. PRF is used to accelerate healing in
maxillary sinus augmentation, socket healing after tooth
extraction, filling of the cyst cavity, treatment of furcation
defects in periodontology, and soft tissue injuries [34].
The positive effects of blood products on healing have
also triggered the development of products in different
concentrations. One of these products, the concentrated
Table 1 Demographic data of patients
Case no. Age Sex Group Implant number
1 20 F Study 1
2 28 M Control 3
3 35 F Study 4
4 32 F Study 4
5 60 M Control 5
6 64 F Study 5
7 52 F Study 5
8 34 M Study 1
9 45 F Control 3
10 48 F Control 2
11 42 M Control 3
12 68 F Control 4
Table 2 Mean ISQ values in the study and control groups
Control group Study group
Immediate 75.75 ± 5.552 78.00 ± 2.828
1st week 73.50 ± 5.226 79.40 ± 2.604
4th week 73.45 ± 5.680 78.60 ± 3.136
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growth factor (CGF), was defined by Sacco in 2006 [35].
CGF also has its own centrifugal technique in a manner
similar to PRF. A longer and denser fibrin matrix with
higher growth factor content was obtained by the differ-
ent centrifugation technique [35].
Regional CGF administration increases FGF-β or
VEGF release, which plays an active role in angiogenesis,
as well as enhancing neutrophil migration by performing
integrin release. It has also been shown that CGF con-
tains such growth factors and CD34-positive cells [35].
It has been reported that CD34-positive cells in the cells
also provide angiogenesis, neovascularization, and vascu-
lar continuity [36, 37].
In an animal study, CGF, PRF, and PRP were placed
separately in the defects formed in the rabbit skull in the
study group; the defects were left empty in the control
group. Histomorphometric analysis revealed statistically
significant differences between control and study groups
in the growth of new bone formation at 6 and 12 weeks.
In the study group, the greatest bone formation was ob-
served in the CGF-treated group but this difference was
not statistically significant [38]. In a study by Takeda et
al. performed on rats, it was observed that cell prolifera-
tion and osteoblastic differentiation in the cell culture
from the CGF-treated group was significantly higher
than in the other groups [39].
In a study by Monov et al. using PRP around the
implant, a higher stability value was obtained in the
study group during the early recovery period (6 weeks)
although difference between the groups was not statisti-
cally significant [23]. Kim et al. reported in a study that
there was a statistically significant increase in bone-
implant contact with PRP administration in the vicinity
of the implant [40].
Based on all these results, it can be said that CGF and
PRF accelerated the implant osseointegration process
and affected the stabilization values positively. It has
been reported that CGF contains more growth factors
than other platelet preparations [35]. It was observed in
our study that CGF has favorable effects on implant
healing period. There is no publication on the effect of
CGF on the stability of dental implants during healing
period. For this reason, we investigated the effect of
CGF on the stability of dental implants in our study.
Conclusions
Considering this data, it appears that application of CGF
enhanced stability of implants and accelerated osseointe-
gration in the early period. CGF has positive effects on
the ISQ value at the first week and fourth week. Further
laboratory studies are needed to demonstrate the posi-
tive effects of blood products on the osseointegration
process at the histopathological level.
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Table 3 Mean ISQ value changes between study and control
groups
Control group Study group
Immediate–1st week −2.25 ± 1.713 1.40 ± 1.847
Immediate–4th week −2.30 ± 2.774 0.60 ± 2.798
1st Week–4th week −0.05 ± 1.572 −0.80 ± 2.215
Pirpir et al. International Journal of Implant Dentistry  (2017) 3:7 Page 5 of 6
Ethics approval and consent to participate
This study was conducted in compliance with the principles of the
Declaration of Helsinki, and approval of the ethics committee required for
the study was obtained from the Ethics Committee of the Karadeniz
Technical University (2015/21). The procedures to be performed were
explained in detail and patients signed the consent forms.
Received: 16 December 2016 Accepted: 16 February 2017
References
1. Raghavendra S, Wood MC, Taylor TD. Early wound healing around
endosseous implants: a review of the literature. Int J Oral Maxillofac
Implants. 2005;20(3):425–31.
2. Oncu E, Bayram B, Kantarci A, Gulsever S, Alaaddinoglu EE. Positive effect of
platelet rich fibrin on osseointegration. Med Oral Patol Oral Cir Bucal. 2016;
21(5):e601–7.
3. Anitua E. Plasma rich in growth factors: preliminary results of use in the
preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;
14(4):529–35.
4. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as
a source of proteins for healing and tissue regeneration. Thromb Haemost.
2004;91(1):4–15.
5. Anitua E, Orive G, Pla R, Roman P, Serrano V, Andia I. The effects of PRGF on
bone regeneration and on titanium implant osseointegration in goats: a
histologic and histomorphometric study. J Biomed Mater Res A. 2009;91(1):
158–65.
6. Bhanot S, Alex JC. Current applications of platelet gels in facial plastic
surgery. Facial Plast Surg. 2002;18(1):27–33.
7. Coetzee JC, Pomeroy GC, Watts JD, Barrow C. The use of autologous
concentrated growth factors to promote syndesmosis fusion in the agility total
ankle replacement. A preliminary study. Foot Ankle Int. 2005;26(10):840–6.
8. Rutkowski JL, Thomas JM, Bering CL, Speicher JL, Radio NM, Smith DM, et al.
Analysis of a rapid, simple, and inexpensive technique used to obtain
platelet-rich plasma for use in clinical practice. J Oral Implantol. 2008;34(1):
25–33.
9. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release
of growth factors and thrombospondin-1 in Choukroun’s platelet-rich fibrin
(PRF): a gold standard to achieve for all surgical platelet concentrates
technologies. Growth Factors. 2009;27(1):63–9.
10. Sohn DS, Heo JU, Kwak DH, Kim DE, Kim JM, Moon JW, et al. Bone
regeneration in the maxillary sinus using an autologous fibrin-rich block
with concentrated growth factors alone. Implant Dent. 2011;20(5):389–95.
11. Gassling VL, Acil Y, Springer IN, Hubert N, Wiltfang J. Platelet-rich plasma
and platelet-rich fibrin in human cell culture. Oral Surg Oral Med Oral Pathol
Oral Radiol Endod. 2009;108(1):48–55.
12. Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound
healing. Front Biosci. 2008;13:3532–48.
13. Anitua E, Sanchez M, Zalduendo MM, de la Fuente M, Prado R, Orive G, et
al. Fibroblastic response to treatment with different preparations rich in
growth factors. Cell Prolif. 2009;42(2):162–70.
14. He L, Lin Y, Hu X, Zhang Y, Wu H. A comparative study of platelet-rich fibrin
(PRF) and platelet-rich plasma (PRP) on the effect of proliferation and
differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 2009;108(5):707–13.
15. Meredith N. A review of nondestructive test methods and their application
to measure the stability and osseointegration of bone anchored
endosseous implants. Crit Rev Biomed Eng. 1998;26(4):275–91.
16. Salvi GE, Lang NP. Diagnostic parameters for monitoring peri-implant
conditions. Int J Oral Maxillofac Implants. 2004;19(Suppl):116–27.
17. Atsumi M, Park SH, Wang HL. Methods used to assess implant stability:
current status. Int J Oral Maxillofac Implants. 2007;22(5):743–54.
18. Meredith N. Assessment of implant stability as a prognostic determinant. Int
J Prosthodont. 1998;11(5):491–501.
19. Sennerby L, Meredith N. Resonance frequency analysis: measuring implant
stability and osseointegration. Compend Contin Educ Dent. 1998;19(5):493–
8. 500, 2; quiz 4.
20. Quesada-Garcia MP, Prados-Sanchez E, Olmedo-Gaya MV, Munoz-Soto E,
Gonzalez-Rodriguez MP, Valllecillo-Capilla M. Measurement of dental
implant stability by resonance frequency analysis: a review of the literature.
Med Oral Patol Oral Cir Bucal. 2009;14(10):e538–46.
21. Nedir R, Bischof M, Szmukler-Moncler S, Bernard JP, Samson J. Predicting
osseointegration by means of implant primary stability. Clin Oral Implants
Res. 2004;15(5):520–8.
22. Barewal RM, Oates TW, Meredith N, Cochran DL. Resonance frequency
measurement of implant stability in vivo on implants with a sandblasted
and acid-etched surface. Int J Oral Maxillofac Implants. 2003;18(5):641–51.
23. Monov G, Fuerst G, Tepper G, Watzak G, Zechner W, Watzek G. The effect of
platelet-rich plasma upon implant stability measured by resonance
frequency analysis in the lower anterior mandibles. Clin Oral Implants Res.
2005;16(4):461–5.
24. Huwiler MA, Pjetursson BE, Bosshardt DD, Salvi GE, Lang NP. Resonance
frequency analysis in relation to jawbone characteristics and during early
healing of implant installation. Clin Oral Implants Res. 2007;18(3):275–80.
25. Kroese-Deutman HC, Vehof JW, Spauwen PH, Stoelinga PJ, Jansen JA.
Orthotopic bone formation in titanium fiber mesh loaded with platelet-rich
plasma and placed in segmental defects. Int J Oral Maxillofac Surg. 2008;
37(6):542–9.
26. Hsu CW, Yuan K, Tseng CC. The negative effect of platelet-rich plasma on
the growth of human cells is associated with secreted thrombospondin-1.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(2):185–92.
27. Shen YX, Fan ZH, Zhao JG, Zhang P. The application of platelet-rich plasma
may be a novel treatment for central nervous system diseases. Med
Hypotheses. 2009;73(6):1038–40.
28. Lam WA, Chaudhuri O, Crow A, Webster KD, Li TD, Kita A, et al. Mechanics
and contraction dynamics of single platelets and implications for clot
stiffening. Nat Mater. 2011;10(1):61–6.
29. Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, et al. Platelet-
released supernatants increase migration and proliferation, and decrease
osteogenic differentiation of bone marrow-derived mesenchymal
progenitor cells under in vitro conditions. Platelets. 2004;15(1):29–35.
30. Choi BH, Zhu SJ, Kim BY, Huh JY, Lee SH, Jung JH. Effect of platelet-rich
plasma (PRP) concentration on the viability and proliferation of alveolar
bone cells: an in vitro study. Int J Oral Maxillofac Surg. 2005;34(4):420–4.
31. Mooren RE, Hendriks EJ, van den Beucken JJ, Merkx MA, Meijer GJ, Jansen
JA, et al. The effect of platelet-rich plasma in vitro on primary cells: rat
osteoblast-like cells and human endothelial cells. Tissue Eng Part A. 2010;
16(10):3159–72.
32. Aghaloo TL, Moy PK, Freymiller EG. Investigation of platelet-rich plasma in
rabbit cranial defects: a pilot study. J Oral Maxillofac Surg. 2002;60(10):1176–81.
33. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, et al.
Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV:
clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 2006;101(3):e56–60.
34. Prakash S, Thakur A. Platelet concentrates: past, present and future. J
Maxillofac Oral Surg. 2011;10(1):45–9.
35. Rodella LF, Favero G, Boninsegna R, Buffoli B, Labanca M, Scari G, et al.
Growth factors, CD34 positive cells, and fibrin network analysis in
concentrated growth factors fraction. Microsc Res Tech. 2011;74(8):772–7.
36. Ademokun JA, Chapman C, Dunn J, Lander D, Mair K, Proctor SJ, et al.
Umbilical cord blood collection and separation for haematopoietic
progenitor cell banking. Bone Marrow Transplant. 1997;19(10):1023–8.
37. Majka M, Janowska-Wieczorek A, Ratajczak J, Ehrenman K, Pietrzkowski Z,
Kowalska MA, et al. Numerous growth factors, cytokines, and chemokines
are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and
megakaryoblasts and regulate normal hematopoiesis in an autocrine/
paracrine manner. Blood. 2001;97(10):3075–85.
38. Kim TH, Kim SH, Sandor GK, Kim YD. Comparison of platelet-rich plasma
(PRP), platelet-rich fibrin (PRF), and concentrated growth factor (CGF) in
rabbit-skull defect healing. Arch Oral Biol. 2014;59(5):550–8.
39. Takeda Y, Katsutoshi K, Matsuzaka K, Inoue T. The effect of concentrated
growth factor on Rat bone marrow cells in vitro and on calvarial bone
healing in vivo. Int J Oral Maxillofac Implants. 2015;30(5):1187–96.
40. Kim SG, Chung CH, Kim YK, Park JC, Lim SC. Use of particulate dentin-plaster of
Paris combination with/without platelet-rich plasma in the treatment of bone
defects around implants. Int J Oral Maxillofac Implants. 2002;17(1):86–94.
Pirpir et al. International Journal of Implant Dentistry  (2017) 3:7 Page 6 of 6
